Mannkind (MNKD) Cash from Investing Activities (2010 - 2026)

Mannkind's (MNKD) quarterly Cash from Investing Activities came in at $18.7 million in Q1 2026, up 214.07% year-on-year from $6.0 million in Q1 2025, and up 106.41% on a QoQ basis from -$292.0 million in Q4 2025.

Mannkind (MNKD) Cash from Investing Activities (2010 - 2026) Analysis & Trends

Mannkind (MNKD) has 17 years of Cash from Investing Activities data on file, last reported at $18.7 million in Q1 2026.

  • On a quarterly basis, Cash from Investing Activities rose 214.07% year-over-year to $18.7 million in Q1 2026; TTM through Mar 2026 was -$292.0 million, a 591.22% decrease from a year earlier, with the FY2025 full-year figure at -$304.8 million, down 215.37% from the prior year.
  • Cash from Investing Activities for Q1 2026 stood at $18.7 million, up from -$292.0 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for MNKD reached as high as $48.2 million in Q4 2024 and fell as low as -$292.0 million in Q4 2025.
  • Historically, Cash from Investing Activities has averaged -$22.3 million across 5 years, with a median of $2.0 million in 2022.
  • On a YoY basis, Cash from Investing Activities climbed as much as 710.82% in 2024 and fell as far as 1606.0% in 2024.
  • Year by year, Cash from Investing Activities stood at $15.0 million in 2022, then tumbled by 152.6% to -$7.9 million in 2023, then jumped by 710.82% to $48.2 million in 2024, then slumped by 705.43% to -$292.0 million in 2025, then surged by 106.41% to $18.7 million in 2026.
  • Per Business Quant data, the three most recent Cash from Investing Activities figures were $18.7 million in Q1 2026, -$292.0 million in Q4 2025, and -$25.1 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,071.81 Bn - -
2 Nanobiotix 1,925.70 Bn 1,925.64 Bn - -
3 Akari Therapeutics 1,062.88 Bn 1,062.88 Bn - -
4 BeOne Medicines 469.09 Bn 464.29 Bn 1.35 Bn -45.51 Mn
5 Vertex Pharmaceuticals 123.09 Bn 115.84 Bn 2.59 Bn -431.90 Mn
6 Regeneron Pharmaceuticals 70.32 Bn 61.57 Bn 3.31 Bn -428.90 Mn
7 Belite Bio 63.36 Bn 63.36 Bn - -
8 Argenx Se 55.90 Bn 50.71 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.69 Bn 34.68 Bn 959.66 Mn -25.54 Mn
10 Mannkind 1.24 Bn 1.11 Bn 82.66 Mn 18.73 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 18.73 Mn
Mar 31, 2026 18.73 Mn
Dec 31, 2025 -291.96 Mn
Dec 31, 2025 -291.96 Mn
Sep 30, 2025 -25.06 Mn
Sep 30, 2025 -25.06 Mn
Jun 30, 2025 6.26 Mn
Jun 30, 2025 6.26 Mn
Mar 31, 2025 5.96 Mn
Mar 31, 2025 5.96 Mn
Dec 31, 2024 48.22 Mn
Dec 31, 2024 48.22 Mn
Sep 30, 2024 -41.26 Mn
Sep 30, 2024 -41.26 Mn
Jun 30, 2024 -55.18 Mn
Jun 30, 2024 -55.18 Mn
Mar 31, 2024 -48.44 Mn
Mar 31, 2024 -48.44 Mn
Dec 31, 2023 -7.90 Mn
Dec 31, 2023 -7.90 Mn